Ortoma (ORT) Investor update summary

Live Q&A

• Live session scheduled for 31 March 2026 at 09:00; advance registration required.

• CEO Fredrik Strömberg, strategic product manager Peter Molyneux and finance lead Magnus Blixt will participate; DNB Carnegie will moderate.

• Topics include how Ortoma Treatment Solution (OTS) works, operations, continued commercialization and the upcoming share issue.

• Questions can be submitted during registration or in writing during the broadcast; a recording will be available on the website afterward.

OTS and intended use

• OTS supports 3D planning and precise positioning of implants for hip, knee and spine surgery.

• The system aims to improve surgical outcomes, reduce complications and repeat operations, and integrate with existing surgical workflows.

• More than 7.5 million orthopedic procedures are performed globally each year across these surgical areas where OTS may be used.